{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T16:45:32Z","timestamp":1790527532603,"version":"4.1.0"},"reference-count":19,"publisher":"Impact Journals, LLC","issue":"29","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2017,7,18]]},"DOI":"10.18632\/oncotarget.17562","type":"journal-article","created":{"date-parts":[[2017,5,2]],"date-time":"2017-05-02T18:13:38Z","timestamp":1493748818000},"page":"47161-47166","source":"Crossref","is-referenced-by-count":26,"title":["Mathematical modeling for Phase I cancer trials: A study of metronomic vinorelbine for advanced non-small cell lung cancer (NSCLC) and mesothelioma patients"],"prefix":"10.18632","volume":"8","author":[{"given":"Fabrice","family":"Barlesi","sequence":"first","affiliation":[{"name":"Aix Marseille University, APHM, Marseille Early Phases Cancer Trials Center CLIP, Marseille, France"},{"name":"Aix Marseille University, SMARTc Unit, INSERM U911, Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane-Charlotte","family":"Imbs","sequence":"additional","affiliation":[{"name":"Aix Marseille University, SMARTc Unit, INSERM U911, Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascale","family":"Tomasini","sequence":"additional","affiliation":[{"name":"Aix Marseille University, APHM, Marseille Early Phases Cancer Trials Center CLIP, Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Greillier","sequence":"additional","affiliation":[{"name":"Aix Marseille University, APHM, Marseille Early Phases Cancer Trials Center CLIP, Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Galloux","sequence":"additional","affiliation":[{"name":"Aix Marseille University, APHM, Marseille Early Phases Cancer Trials Center CLIP, Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albane","family":"Testot-Ferry","sequence":"additional","affiliation":[{"name":"Aix Marseille University, APHM, Marseille Early Phases Cancer Trials Center CLIP, Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e9lanie","family":"Garcia","sequence":"additional","affiliation":[{"name":"Aix Marseille University, APHM, Department of Pharmacology, Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Elharrar","sequence":"additional","affiliation":[{"name":"Aix Marseille University, APHM, Marseille Early Phases Cancer Trials Center CLIP, Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annick","family":"Pelletier","sequence":"additional","affiliation":[{"name":"Aix Marseille University, APHM, Marseille Early Phases Cancer Trials Center CLIP, Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Andr\u00e9","sequence":"additional","affiliation":[{"name":"Aix Marseille University, SMARTc Unit, INSERM U911, Marseille, France"},{"name":"Aix Marseille University, APHM, Department of Pediatric Hematology and Oncology, Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Mascaux","sequence":"additional","affiliation":[{"name":"Aix Marseille University, APHM, Marseille Early Phases Cancer Trials Center CLIP, Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Lacarelle","sequence":"additional","affiliation":[{"name":"Aix Marseille University, SMARTc Unit, INSERM U911, Marseille, France"},{"name":"Aix Marseille University, APHM, Department of Pharmacology, Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raouf El","family":"Cheikh","sequence":"additional","affiliation":[{"name":"Aix Marseille University, SMARTc Unit, INSERM U911, Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rapha\u00ebl","family":"Serre","sequence":"additional","affiliation":[{"name":"Aix Marseille University, SMARTc Unit, INSERM U911, Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Ciccolini","sequence":"additional","affiliation":[{"name":"Aix Marseille University, SMARTc Unit, INSERM U911, Marseille, France"},{"name":"Aix Marseille University, APHM, Department of Pharmacology, Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Barbolosi","sequence":"additional","affiliation":[{"name":"Aix Marseille University, SMARTc Unit, INSERM U911, Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2017,5,2]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nrclinonc.2014.89","article-title":"Metronomics: towards personalized chemotherapy?","volume":"11","author":"Pasquier","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"key":"2","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/nrclinonc.2015.204","article-title":"Computational oncology\u2014mathematical modelling of drug regimens for precision medicine","volume":"13","author":"Andr\u00e9","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"3","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s00280-014-2546-1","article-title":"Metronomics chemotherapy: time for computational decision support","volume":"74","author":"Barlesi","year":"2014","journal-title":"Cancer Chemother Pharmacol"},{"key":"4","doi-asserted-by":"crossref","first-page":"6454","DOI":"10.1158\/1078-0432.CCR-09-0970","article-title":"Dose-ranging study of metronomic oral vinorelbine in patients with advanced refractory cancer","volume":"15","author":"Pavlidis","year":"2009","journal-title":"Clin Cancer Res"},{"key":"5","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1007\/s00280-011-1580-5","article-title":"Phase I trial of metronomic oral vinorelbine in patients with advanced cancer","volume":"68","author":"Sparano","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"key":"6","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1186\/1471-2407-13-263","article-title":"Dose selection trial of metronomic oral vinorelbine monotherapy in patients with metastatic cancer: a hellenic cooperative oncology group clinical translational study","volume":"13","author":"Fountzilas","year":"2013","journal-title":"BMC Cancer"},{"key":"7","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1179\/1973947812Y.0000000050","article-title":"A phase II study of metronomic oral vinorelbine administered in the second line and beyond in non-small cell lung cancer (NSCLC): a phase II study of the Hellenic Oncology Research Group","volume":"25","author":"Agelaki","year":"2013","journal-title":"J Chemother"},{"key":"8","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1007\/s00280-005-1025-0","article-title":"The absolute bioavailability of oral vinorelbine in patients with solid tumors","volume":"56","author":"Sullivan","year":"2005","journal-title":"Cancer Chemother Pharmacol"},{"key":"9","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.semcancer.2015.09.002","article-title":"Metronomic reloaded: Theoretical models bringing chemotherapy into the era of precision medicine","volume":"35","author":"Ciccolini","year":"2015","journal-title":"Semin Cancer Biol"},{"key":"10","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1186\/s12885-016-2308-z","article-title":"A phase Ia\/Ib clinical trial of metronomic chemotherapy based on a mathematical model of oral vinorelbine in metastatic non-small cell lung cancer and malignant pleural mesothelioma: rationale and study protocol","volume":"16","author":"Barlesi","year":"2016","journal-title":"BMC Cancer"},{"key":"11","doi-asserted-by":"crossref","first-page":"4713","DOI":"10.1200\/JCO.2002.02.140","article-title":"Model of chemotherapy-induced myelosuppression with parameter consistency across drugs","volume":"20","author":"Karlsson","year":"2002","journal-title":"J Clin Oncol"},{"key":"12","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s00228-002-0506-x","article-title":"A simultaneous oral\/intravenous population pharmacokinetic model for vinorelbine","volume":"58","author":"Puozzo","year":"2002","journal-title":"Eur J Clin Pharmacol"},{"key":"13","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/nrclinonc.2016.64","article-title":"Pharmacokinetics of metronomic chemotherapy: a neglected but crucial aspect","volume":"13","author":"Kerbel","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"14","doi-asserted-by":"crossref","first-page":"373","DOI":"10.2217\/fon.15.306","article-title":"Metronomic oral vinorelbine in advanced breast cancer and non-small-cell lung cancer: current status and future development","volume":"12","author":"Bocci","year":"2016","journal-title":"Future Oncol"},{"key":"15","first-page":"4931","article-title":"Mathematical Modeling of Cancer Immunotherapy and Its Synergy with Radiotherapy","volume":"6","author":"Barbolosi","year":"2016","journal-title":"Cancer Res"},{"key":"16","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1186\/s12885-015-1354-2","article-title":"Metronomic oral vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer: results of a phase II trial (MOVE trial)","volume":"15","author":"Amoroso","year":"2015","journal-title":"BMC Cancer"},{"key":"17","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1098\/rstl.1825.0026","article-title":"On the nature of the function expressive of the law of human mortality and on a new model of determining life contingencies","volume":"115","author":"Gompertz","year":"1825","journal-title":"Phil Trans R Soc"},{"key":"18","first-page":"6938","article-title":"Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs","volume":"62","author":"Kerbel","year":"2002","journal-title":"Cancer Res"},{"key":"19","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1056\/NEJM197111182852108","article-title":"Tumor angiogenesis: therapeutic implications","volume":"285","author":"Folkman","year":"1971","journal-title":"N Engl J Med"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.17562","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,10]],"date-time":"2020-05-10T20:35:55Z","timestamp":1589142955000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.17562"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,2]]},"references-count":19,"journal-issue":{"issue":"29","published-print":{"date-parts":[[2017,7,18]]}},"alternative-id":["17562","28525370"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.17562","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,2]]}}}